Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Energy Firm Posts Solid Q2, Positions Itself for Price Uncertainty

A Haywood report explains why TORC Oil & Gas is "well positioned to ride out the current tumultuous oil price environment." In a May 6 research note, Haywood analyst Christopher Jones reported that TORC Oil & Gas Ltd. (TOG:TSX) had a "sound" Q2 FY20 and made stra...
Streetwise Reports | May 15, 2020 |

Biopharma Co. Makes Major Headway Toward Clinical Trials for Treatment of Stroke

(CLICK IMAGE TO PLAY VIDEO) Finding an effective method of preventing the possibility of stroke is something that medical science has grappled with for decades. Now, a Vancouver-based clinical stage biopharmaceutical development company looks to be making significa...
Dave Jackson | June 16, 2021 |

Soliton Shares Rise on Announcement It Will Report Clinical Data at National Dermatology Conference

Soliton Inc. shares traded 10% higher today after advising that later this month it will present the data from clinical trials for its Rapid Acoustic Pulse device used in the treatment of keloid and hypertrophic scars at the American Society for Dermatologic Surgery Annual Mee...
Streetwise Reports | October 10, 2019 |

Leap Therapeutics Lunges Forward on $132M Licensing Deal and $27M Equity Raise

Shares of Leap Therapeutics jumped 60% after the company reported that it signed an exclusive option and license agreement for its immuno-oncology drug DKN-01 with BeiGene in the Asia Pacific region excluding Japan. The firm also secured an additional $27 million in equity fin...
Streetwise Reports | January 6, 2020 |

BARDA Award Provides 'Lift-off for Biotech's COVID Vaccine'

The ways in which Moderna is to use the funds are explained and an update on its coronavirus vaccine is provided in a ROTH Capital Partners report. In an April 19 research note, ROTH Capital Partners analyst Yasmeen Rahimi reported that the Biomedical Advanc...
Streetwise Reports | April 23, 2020 |

Westwater Shares Charge Higher after Demonstrating Simulated Full-Scale Battery Graphite Processing

Shares of Westwater Resources traded higher on greater than 100-times average daily volume after the company reported that positive independent test results on ULTRA-PMG™ demonstrated successful simulated full-scale processing of battery graphite. Energy materials ...
Streetwise Reports | June 3, 2020 |

Exploring Four High-Grade Gold Projects in a “Bonanza” District

The circus of despair that has been 2020 was – among other things – a transformative time for the vast majority of industries, businesses and people around the world. From the utter collapse of global stock markets in mid-March to a soaring gold price that peaked in early Aug...
Oliver Gray | January 7, 2021 |

Small-Cap Pharma Fast-Tracking Repurposed Drug for Covid-19

Algernon Pharmaceuticals is quickly moving ahead with a multinational Phase 2b/3 trial for Ifenprodil. Algernon Pharmaceuticals Inc. (AGN:CSE; AGNPF:OTCQB; AGW:FSE) , a Canada-based clinical stage drug development company that focuses on drug repurposing, believes ...
Streetwise Reports | May 28, 2020 |

NervGen Pharma: A “Blockbuster Drug” in the Making?

It has the potential to be one of the most disruptive pharmaceutical drug therapies of the modern era, especially for treating Alzheimer’s disease. And that gives it considerable “blockbuster drug” potential – a tantalising opportunity tha...
Marc Davis | June 25, 2021 |

Buzz on the Bullboards: Key Goals Behind Top Investor’s Moves

(Image via HEXO Corp.) At Stockhouse, investor focus is on companies whose valuations seem a little more firmly rooted in down on planet Earth. When it comes to the most popular stocks over the previous week, three names are dominating, especially where health care ...
Stockhouse Editorial | September 22, 2021 |
1 2